Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer

DOI: 10.4236/abcr.2013.24022   PDF   HTML     5,403 Downloads   11,317 Views   Citations

Abstract

Aim: Firstly, to quantify active healthcare professional (HCP) time and costs associated with subcutaneous (SC) administration of trastuzumab (Herceptin?) compared with the standard intravenous infusion (IV) in the treatment of patients with HER2-positive early breast cancer within the adjuvant PrefHer trial setting; secondly, to measure patient time in the care unit and patient infusion chair time for both routes of administration. Methods: A UK multi-centre prospective, observational Time and Motion study was conducted alongside the PrefHer trial (ClinicalTrials.gov id: NCT01401166). Trained observers measured the duration of each SC and IV related task that HCPs undertook and recorded patient time in the chemotherapy unit and infusion chair. The type and quantity of medical consumables used with each route of administration were also collected. Twenty-four patient episodes were recorded (12 SC, 12 IV). Mean total administration time was calculated as the mean sum of task times, both for IV and SC formulations. The mean cost of each route of administration was calculated as the mean cost of HCP time plus the mean cost of consumables used. HCP time was costed using Personal Social Services Research Unit. Consumables were costed using hospital pharmacy data and online sources. Results: Mean active HCP time for IV administration was 92.6 minutes compared with 24.6 minutes for SC administration. The mean cost for IV preparation and administration was £144.96 (£132.05 of HCP time and £12.92 of consumables) versus £33.15 (£31.99 of HCP time and £1.17 of consumables) for SC administration. Mean time spent in the care unit and in the infusion chair was 94.5 minutes and 75 minutes respectively for IV, and 30.3 minutes and 19.8 minutes for SC. SC administration of trastuzumab could translate to a time saving of 68 minutes (versus IV) with a total cost saving of £111.81 per patient episode. This equates to a potential saving of £2012.58 over a full course of adjuvant treatment (18 cycles). Conclusion: Substituting IV infusion with SC administration of trastuzumab may lead to a substantial reduction in active HCP time, patient chair and unit time, consumable use and overall costs. The reduced patient chair and unit time could provide increased capacity within existing resources.

Share and Cite:

Burcombe, R. , Chan, S. , Simcock, R. , Samanta, K. , Percival, F. and Barrett-Lee, P. (2013) Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research, 2, 133-140. doi: 10.4236/abcr.2013.24022.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Office for National Statistics, London, “Cancer Statistics Registrations England (Series MB1) No 42, 2011,” 2013.http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html
[2] Welsh Cancer Intelligence and Surveillance Unit Cardiff, “Cancer Incidence in Wales, 2007-2011,” 2013. http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=66227
[3] Office for National Statistics, “Breast Cancer: Incidence, Mortality and Survival, 2010. Female Breast Cancer in England: Incidence and Mortality,” 2012. http://www.ons.gov.uk/ons/dcp 171780_280355.pdf
[4] “Herceptin (Trastuzumab) Summary of Product Characteristics,” 2013. http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500 074922.pdf
[5] S. Vescial, A. K. Baumgartner, V. R. Jacobs, M. Kiechle-Bahat, A. Rody, S. Loibl and N. Harbeck, “Management of Venous Port Systems in Oncology: A Review of Current Evidence,” Annals of Oncology, Vol. 19, No. 1, 2008, pp. 9-15. http://dx.doi.org/10.1093/annonc/mdm272
[6] S. Hamizi, G. Freyer, N. Bakrin, E. Henin, A. Mohtaram, O. Le Saux and C. Falandry, “Subcutaneous Trastuzumab: Development of a New Formulation for Treatment of HER2-Positive Early Breast Cancer,” OncoTargets and Therapy, Vol. 6, 2013, pp. 89-94.
[7] Department of Health, “Improving Outcomes: A Strategy for Cancer,” 2011. https://www.gov.uk/ government/uploads/system/uploads/attachment_data/file/135516/dh_123394.pdf.pdf
[8] Personal Social Services Research Unit (PSSRU) Unit “Costs of Health & Social Care,” 2011. http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf
[9] Roche Products Ltd., “Herceptin (Trastuzumab) Algorithm, RXUKHERC00419,” Data on File, 2012.
[10] Roche Products Ltd., “Herceptin Mean Number of Doses in 1L HER2+ mBC. RXUKDONF00248,” Data on File. 2012.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.